Jefferies Financial Group Analysts Increase Earnings Estimates for Sanofi (NASDAQ:SNY)

Sanofi (NASDAQ:SNYGet Rating) – Jefferies Financial Group boosted their FY2022 earnings estimates for shares of Sanofi in a research report issued to clients and investors on Tuesday, April 19th. Jefferies Financial Group analyst P. Welford now forecasts that the company will post earnings per share of $4.25 for the year, up from their previous forecast of $4.20. Jefferies Financial Group also issued estimates for Sanofi’s FY2023 earnings at $4.64 EPS, FY2024 earnings at $5.04 EPS and FY2025 earnings at $5.61 EPS.

A number of other research analysts have also commented on SNY. UBS Group dropped their price objective on shares of Sanofi from €122.00 ($131.18) to €121.00 ($130.11) and set a “buy” rating on the stock in a research note on Friday, April 8th. Barclays upped their price objective on Sanofi from €90.00 ($96.77) to €105.00 ($112.90) in a research note on Thursday, April 14th. Morgan Stanley increased their price objective on Sanofi from €108.00 ($116.13) to €110.00 ($118.28) in a research report on Monday, March 28th. Stifel Nicolaus began coverage on Sanofi in a report on Monday, February 28th. They issued a “buy” rating on the stock. Finally, Credit Suisse Group increased their price target on Sanofi from €96.00 ($103.23) to €105.00 ($112.90) in a report on Monday, March 28th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat, Sanofi currently has an average rating of “Buy” and a consensus target price of $95.00.

SNY stock opened at $55.85 on Thursday. Sanofi has a 12 month low of $46.92 and a 12 month high of $58.10. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.44 and a quick ratio of 1.03. The company has a market cap of $141.15 billion, a price-to-earnings ratio of 19.00, a price-to-earnings-growth ratio of 1.23 and a beta of 0.55. The company has a fifty day moving average price of $52.60 and a 200 day moving average price of $51.02.

Sanofi (NASDAQ:SNYGet Rating) last issued its quarterly earnings data on Friday, February 4th. The company reported $0.79 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.76 by $0.03. The company had revenue of $11.43 billion during the quarter, compared to analysts’ expectations of $11.78 billion. Sanofi had a return on equity of 24.61% and a net margin of 16.52%.

Large investors have recently added to or reduced their stakes in the business. First Community Trust NA purchased a new stake in shares of Sanofi during the 4th quarter worth approximately $26,000. Herold Advisors Inc. purchased a new stake in Sanofi during the third quarter worth $27,000. Pinnacle Bancorp Inc. grew its holdings in Sanofi by 49.0% in the first quarter. Pinnacle Bancorp Inc. now owns 587 shares of the company’s stock valued at $30,000 after purchasing an additional 193 shares during the last quarter. Glassman Wealth Services increased its position in shares of Sanofi by 56.1% in the fourth quarter. Glassman Wealth Services now owns 690 shares of the company’s stock valued at $35,000 after buying an additional 248 shares in the last quarter. Finally, Clearstead Advisors LLC raised its stake in shares of Sanofi by 84.6% during the 4th quarter. Clearstead Advisors LLC now owns 709 shares of the company’s stock worth $36,000 after buying an additional 325 shares during the last quarter. Hedge funds and other institutional investors own 12.65% of the company’s stock.

About Sanofi (Get Rating)

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products.

See Also

Earnings History and Estimates for Sanofi (NASDAQ:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with's FREE daily email newsletter.